RUSH, NY – April 27, 2017 – iuvo BioScience is pleased to announce the addition of Daniel Roberts as Principal Scientist, Genetic Toxicology, to further expand iuvo’s offerings.
“Dan will head up our genetox offerings, and be a tremendous asset to our technical team,” said Dr. Mary Richardson, iuvo’s Chief Scientific Officer. Dr. Richardson added that with the addition, iuvo will have in house capability to address every section of ISO 10993 biocompatibility testing as well.
Mr. Roberts comes to iuvo most recently from Bristol-Myers Squibb Company where he was a Study Director and researcher in Genetic Toxicology supporting drug safety assessment. He is also a former Chairman of the Board of the Genetic Toxicology Association (2016) and is currently a co-leader of the Flow Cytometry and other Technologies subgroup, part of ILSI-HESI’s GTTC Mode of Action Workgroup.
“Mr. Roberts is a great addition to our team, and he brings experience and expertise that greatly augments our capabilities,” added iuvo CEO Ben Burton.
Mr. Roberts has an MS in biotechnology from Johns Hopkins University and is currently completing his PhD in Toxicology at Rutgers University.
About iuvo BioScience
iuvo BioScience is a Partner Research Organization (PRO) serving the medical device and pharmaceutical industries. The Company offers technical and regulatory consulting services and contract laboratory services out of its location in Rush, New York, with strong expertise in toxicology, analytical chemistry and microbiology. More information on the Company’s services and capabilities is available on the Company’s website at www.iuvobioscience.com.
For more information, contact John Lanzafame at John.Lanzafame@iuvobioscience.com or (585) 533 1672.
